Literature DB >> 11271790

Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study.

C P Williams1, D F Child, P R Hudson, G K Davies, M G Davies, R John, P S Anandaram, A R De Bolla.   

Abstract

AIMS: To investigate whether increasing the daily baseline of gut calcium can cause a gradual downregulation of the active intestinal transport of calcium via reduced parathyroid hormone (PTH) mediated activation of vitamin D, and to discuss why such a mechanism might prevent calcium oxalate rich stones. To demonstrate the importance of seasonal effects upon the evaluation of such data.
METHODS: Within an intensive 24 hour urine collection regimen, daily calcium supplementation (500 mg) was given to five stone formers for a 10 week period during a six month crossover study. In a further population of patients on follow up for previous renal stone disease, observations were made on 1066 24 hour urine samples collected over five years in respect of seasonal effects relevant to the interpretation of the study.
RESULTS: In the group of patients on calcium supplements the following results were found. During calcium supplementation, the proportion of urine calcium to oxalate was higher (increased calcium to oxalate molar ratio), the 24 hour urine product of calcium and oxalate did not rise, and urine oxalate was lower during the first six weeks of supplementation. Twenty four hour urine calcium was 10.2% higher than baseline in the final four weeks of the 10 weeks of supplementation. Twenty four hour urine phosphate was 11.4% lower during the first six weeks of supplementation, but then rose while the patients were still on supplementation; renal tubular reabsorption of phosphate (TmP/GFR) mirrored the urine phosphate changes inversely. PTH was higher after stopping supplementation, but 1,25-(OH)2-cholecalciferol changes were not detected. In the 1066 urine samples collected over five years the following results were found. Calcium and oxalate excretion correlated positively and not inversely. Urine calcium and phosphate excretion were 5.5% and 2.5% higher, respectively, in "light" months of the year compared with "dark" months. A post summer decline in both urine calcium and urine phosphate was relevant to the interpretation of the study.
CONCLUSIONS: Regular calcium supplementation does not raise the product of calcium and oxalate in urine and the proportion of oxalate to calcium is reduced. The underlying mechanisms of the changes seen in phosphate, calcium, and PTH and the observations on 1,25-(OH)2-cholecalciferol are not clear. Observed changes in phosphate could possibly be part of a calcium regulating feedback loop operating over a period of weeks. In evaluating these mechanisms background seasonal effects are important. It is possible that "programming" of the gut mucosa in terms of calcium transport is a major determinant of the relation between calcium and oxalate concentrations in urine and their relative abundance. Increased oral calcium, in association with a reduction of the relative proportion absorbed, may be pertinent to the prevention of calcium oxalate rich stones.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11271790      PMCID: PMC1731261          DOI: 10.1136/jcp.54.1.54

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  49 in total

1.  Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults.

Authors:  J Lemann; J A Pleuss; E M Worcester; L Hornick; D Schrab; R G Hoffmann
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

2.  Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia.

Authors:  Q Cai; S F Hodgson; P C Kao; V A Lennon; G G Klee; A R Zinsmiester; R Kumar
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

3.  Tumor-induced osteomalacia--unveiling a new hormone.

Authors:  M J Econs; M K Drezner
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

4.  Circadian rhythms of urinary saturation levels of calcium oxalate and calcium phosphate in normal male individuals.

Authors:  Y Ogawa
Journal:  Hinyokika Kiyo       Date:  1993-09

Review 5.  Vitamin D.

Authors:  D R Fraser
Journal:  Lancet       Date:  1995-01-14       Impact factor: 79.321

6.  [Dietary control for out-patients in urinary stone clinic].

Authors:  T Kato; M Yanagawa; T Hioki; M Sakurai; K Yamakawa; T Araki; I Yamamoto; K Arima; H Tochigi; J Kawamura
Journal:  Hinyokika Kiyo       Date:  1993-07

7.  Determinants of serum 1,25-dihydroxyvitamin D concentration in healthy premenopausal subjects.

Authors:  S C Ho; D Mac Donald; C Chan; Y K Fan; S S Chan; R Swaminathan
Journal:  Clin Chim Acta       Date:  1994-10-14       Impact factor: 3.786

8.  A common molecular basis for three inherited kidney stone diseases.

Authors:  S E Lloyd; S H Pearce; S E Fisher; K Steinmeyer; B Schwappach; S J Scheinman; B Harding; A Bolino; M Devoto; P Goodyer; S P Rigden; O Wrong; T J Jentsch; I W Craig; R V Thakker
Journal:  Nature       Date:  1996-02-01       Impact factor: 49.962

9.  Effect of dietary intake on urinary oxalate excretion in calcium renal stone formers.

Authors:  M Masai; H Ito; T Kotake
Journal:  Br J Urol       Date:  1995-12

10.  Circadian variations in the risk of urinary calcium oxalate stone formation.

Authors:  M Robert; J O Roux; F Bourelly; A M Boularan; J Guiter; L Monnier
Journal:  Br J Urol       Date:  1994-09
View more
  8 in total

1.  Analysis of urinary calculi using an infrared microspectroscopic surface reflectance imaging technique.

Authors:  Jennifer C Anderson; James C Williams; Andrew P Evan; Keith W Condon; André J Sommer
Journal:  Urol Res       Date:  2007-01-05

2.  Urinary evaluation after RYGBP: a lithogenic profile with early postoperative increase in the incidence of urolithiasis.

Authors:  Antonio Carlos Valezi; Paulo Emilio Fuganti; Jorge Mali Junior; Vinicius Daher Delfino
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

3.  Problems in the metabolic evaluation of renal stone disease: audit of intra-individual variation in urine metabolites.

Authors:  Pallavoor S Anandaram; Alan R De Bolla; Peter R Hudson; Gareth K Davies; Purnendu Majumdar; Clive P Williams
Journal:  Urol Res       Date:  2006-05-06

Review 4.  Calcium citrate and vitamin D in the treatment of osteoporosis.

Authors:  José Manuel Quesada Gómez; Josep Blanch Rubió; Manuel Díaz Curiel; Adolfo Díez Pérez
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 5.  Calcium supplementation for prevention of primary hypertension.

Authors:  Gabriela Cormick; Agustín Ciapponi; María Luisa Cafferata; María Sol Cormick; José M Belizán
Journal:  Cochrane Database Syst Rev       Date:  2022-01-11

Review 6.  Calcium supplementation for prevention of primary hypertension.

Authors:  Gabriela Cormick; Agustín Ciapponi; María Luisa Cafferata; José M Belizán
Journal:  Cochrane Database Syst Rev       Date:  2015-06-30

Review 7.  Calcium supplementation for prevention of primary hypertension.

Authors:  Gabriela Cormick; Agustín Ciapponi; María Luisa Cafferata; María Sol Cormick; José M Belizán
Journal:  Cochrane Database Syst Rev       Date:  2021-08-10

8.  The relationship between kidney stones and dietary habits.

Authors:  Akeel T Al-Kazwini; Maan S Al-Arif; Suhad S Abu-Mweis; Tarek F Al-Hammouri
Journal:  Res Rep Urol       Date:  2019-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.